Contacts

J. Enrique Dominguez-Munoz, PhD, MD

CONTACT

+34981951364 juan.enrique.dominguez.munoz@sergas.es

Sponsors

Lead Sponsor

Hospital Clinico Universitario de Santiago

Collaborators

Complejo Hospitalario de Navarra
Karolinska Institutet
San Raffaele University Hospital, Italy
Beaujon Hospital

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Pathologically confirmed unresectable, locally advanced or metastatic, pancreatic cancer.
•2. Tumour located in the head of the pancreas.
•3. Dilated main pancreatic duct confirmed by imaging methods (CT scan, MRI and/or EUS).
•4. Significant weight loss (≥5% of the usual body weight) at screening.
•5. Life expectancy of at least six months at screening.
•6. Signed informed consent to the study.

Exclusion Criteria

•1. Hypersensitivity to pancreatin of porcine origin or to any of the excipients.
•2. Patients on neoadjuvant therapy, or in whom neoadjuvant therapy is planned.
•3. Patients already on PERT.
•4. Prior history of upper gastrointestinal or pancreatic surgery.
•5. Short life expectancy (shorter than 6 months).
•6. Patients on second line or beyond chemotherapy (those who failed with first line chemotherapy therapy).
•7. Patients in whom a pancreatic stent has been placed.
•8. Unsolved gastric outlet obstruction.
•9. Unwillingness to participate in the study.
•10. Inability to comply with the study visits and study protocol, whatever the reason.

Related studies

RECRUITINGEARLY Phase 1

A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer

NCT07198659 · Unresectable Pancreatic Cancer

RECRUITINGPhase 2

Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers

NCT06135896 · Unresectable Pancreatic Cancer, Unresectable Bile Duct Carcinoma, and more

RECRUITINGPhase 1/2

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

NCT04789486 · Non-small Cell Lung Cancer, Advanced Pancreatic Adenocarcinoma, and more

RECRUITINGPhase 1

Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)

NCT06278454 · Unresectable Pancreatic Cancer

Active Not RecruitingNA

Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer

NCT04002479 · Pancreatic Cancer, Unresectable Pancreatic Cancer, and more

View all related studies →

Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Contacts

Sponsors

Related studies

A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer

Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)

Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer

Trial snapshot

Condition

Locations shown

For caregivers